Claims for Patent: 8,642,538

Summary for Patent: 8,642,538

Title:	Macrocyclic hepatitis C serine protease inhibitors
Abstract:	The present invention relates to novel macrocyclic compounds and methods of treating a hepatitis C infection in a subject in need of such therapy with said macrocyclic compounds. The present invention further relates to pharmaceutical compositions comprising the compounds of the present invention, or pharmaceutically acceptable salts, esters, or prodrugs thereof, in combination with a pharmaceutically acceptable carrier or excipient.
Inventor(s):	Ku; Yiyin (Buffalo Grove, IL), McDaniel; Keith F. (Wauconda, IL), Chen; Hui-Ju (Grayslake, IL), Shanley; Jason P. (Chicago, IL), Kempf; Dale J. (Libertyville, IL), Grampovnik; David J. (Waukegan, IL)
Assignee:	AbbVie, Inc. (North Chicago, IL)
Application Number:	13/439,551
Patent Claims:	1. A compound of formula I or I': ##STR00031## or a pharmaceutically acceptable salt thereof, wherein: J is absent, optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, --C(O)--, --O--C(O)--, --N(R.sub.3)--C(O)--, --C(S)--, --C(.dbd.NR.sub.4)--, --S(O)--, --S(O.sub.2)--, or --N(R.sub.3)--; A is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, optionally substituted arylalkyl, optionally substituted alkoxy, optionally substituted heteroaryl, optionally substituted heterocyclic, or optionally substituted carbocyclic; Each R.sub.1 is independently selected from (i) halogen, hydroxy, amino, --CN, --CF.sub.3, --N.sub.3, --NO.sub.2, --OR.sub.4, --SR.sub.4, --SOR.sub.4, --SO.sub.2R.sub.4, --N(R.sub.3)S(O).sub.2--R.sub.4, --N(R.sub.3)(SO.sub.2)NR.sub.3R.sub.4, --NR.sub.3R.sub.4, --C(O)--OR.sub.4, --C(O)R.sub.4, --C(O)NR.sub.3R.sub.4, or --N(R.sub.3)C(O)R.sub.4; (ii) optionally substituted aryl; (iii) optionally substituted heteroaryl; (iv) optionally substituted heterocyclic; (v) optionally substituted carbocyclic; or (vi) optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; G is -E-R.sub.5; wherein E is absent; optionally substituted alkylene, optionally substituted alkenylene, optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; or --O--, --S--, --N(R.sub.3)--, --N(R.sub.3)S(O.sub.p)--, --N(R.sub.3)C(O)--, --N(R.sub.3) C(O)S(O.sub.p)--, --OS(O.sub.p)--, --C(O)S(O.sub.p)--, or --C(O)N(R.sub.3)S(O.sub.p)--; p is 0, 1, or 2; R.sub.5 is H; optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted carbocyclic, optionally substituted heterocyclic, optionally substituted aryl, or optionally substituted heteroaryl; R.sub.3 and R.sub.4 are each independently selected at each occurrence from the following: optionally substituted alkyl, optionally substituted alkenyl or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl; optionally substituted heteroaryl; optionally substituted heterocyclic; optionally substituted carbocyclic; or hydrogen; L is absent or is selected from optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; j=0, 1, 2, 3, or 4; k=0, 1, 2, or 3; m=0, 1, or 2; n is 0, 1, 2, 3, or 4; and denotes a carbon-carbon single or double bond, Y is --C(R'')--, R' and R'' taken together with the carbon atoms to which they are attached form an aryl or heteroaryl ring, each said ring is optionally substituted. 2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein k=3, j=1 and L is absent. 3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R.sub.1 is hydrogen or halogen; E is --NHS(O)-- or --NHS(O.sub.2)--, and R.sub.5 is cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, or imidazolyl, each of which is optionally substituted. 4. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein J is --C(O)-- and A is optionally substituted --C.sub.1-C.sub.8 alkyl, containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; optionally substituted aryl, optionally substituted --C.sub.1-C.sub.8 alkoxy, optionally substituted heteroaryl, optionally substituted --C.sub.3-C.sub.12 cycloalkyl, or optionally substituted --C.sub.3-C.sub.12 heterocycloalkyl. 5. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R' and R'' together form an optionally substituted aryl. 6. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein R' and R'', and the atoms to which each is attached, form an aryl which is substituted by (R.sub.2).sub.x, wherein each R.sub.2 is independently selected from (i) halogen, hydroxy, amino, --CN, --CF.sub.3, --N.sub.3, --NO.sub.2, --OR.sub.4, --SR.sub.4, --SOR.sub.4, --SO.sub.2R.sub.4, --NHS(O.sub.2)--R.sub.4, --NHS(O.sub.2)NR.sub.3R.sub.4, --NR.sub.3R.sub.4, --C(O)OR.sub.4, --C(O)R.sub.4, --C(O)NR.sub.3R.sub.4, or --N(R.sub.3)C(O)R.sub.4; (ii) optionally substituted aryl; (iii) optionally substituted heteroaryl; (iv) optionally substituted heterocyclic; (v) optionally substituted carbocyclic; or (iv) optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; and x is 0, 1, 2, 3, or 4. 7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier or excipient. 8. A method of treating a hepatitis C viral infection in a subject, comprising administering to the subject a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof. 9. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein E is --N(R.sub.3)S(O.sub.p)--, R.sub.3 is H, p is 2, and R.sub.5 is optionally substituted carbocyclic. 10. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein R.sub.5 is optionally substituted cyclopropyl. 11. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein E is --N(R.sub.3)S(O.sub.p)--, R.sub.3 is H, p is 2, and R.sub.5 is optionally substituted heteroaryl. 12. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein J is --C(O)-- and A is optionally substituted heteroaryl. 13. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein A is substituted heteroaryl. 14. The compound of claim 12, or a pharmaceutically acceptable salt thereof, wherein A is pyrazinyl. 15. The method of claim 8, wherein: k=3; j=1; L is absent; R' and R'', and the atoms to which each is attached, form an aryl which is substituted by (R.sub.2).sub.x; each R.sub.2 is independently selected from (i) halogen, hydroxy, amino, --CN, --CF.sub.3, --N.sub.3, --NO.sub.2, --OR.sub.4, --SR.sub.4, --SOR.sub.4, --SO.sub.2R.sub.4, --NHS(O.sub.2)--R.sub.4, --NHS(O.sub.2)NR.sub.3R.sub.4, --NR.sub.3R.sub.4, --C(O)OR.sub.4, --C(O)R.sub.4, --C(O)NR.sub.3R.sub.4, or --N(R.sub.3)C(O)R.sub.4; (ii) optionally substituted aryl; (iii) optionally substituted heteroaryl; (iv) optionally substituted heterocyclic; (v) optionally substituted carbocyclic; or (iv) optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl, each containing 0, 1, 2, or 3 heteroatoms selected from O, S, or N; and x is 0, 1, 2, 3, or 4. 16. The method of claim 8, wherein E is --N(R.sub.3)S(O.sub.p)--, R.sub.3 is H, p is 2, and R.sub.5 is optionally substituted carbocyclic. 17. The method of claim 8, wherein E is --N(R.sub.3)S(O.sub.p)--, R.sub.3 is H, p is 2, and R.sub.5 is optionally substituted heteroaryl. 18. The method of claim 8, wherein J is --C(O)-- and A is optionally substituted heteroaryl. 19. The method of claim 18, wherein A is substituted heteroaryl. 20. The method of claim 18, wherein A is pyrazinyl.